New York, Jan 5 (IANS) US pharma giant Pfizer’s antiviral drug Paxlovid (Nirmatrelvir-ritonavir) does not reduce the risk of developing long Covid for vaccinated, non-hospitalised individuals, according to a study. A team of researchers from Univesity of California San Francisco (UCSF) revealed that among Paxlovid users, a higher proportion of individuals with acute symptoms rebound and test-positivity than previously reported. The findings appeared in the Journal of Medical Virology. Paxlovid treatment for acute Covid-19 has been shown to be effective for high-risk unvaccinated individuals. But the effect of the treatment on long Covid risk, including whether it protects vaccinated people f
Hence then, the article about pfizer s paxlovid antiviral drug does not reduce risk of long covid study was published today ( ) and is available onNews room odisha ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Pfizer’s Paxlovid antiviral drug does not reduce risk of long Covid: Study )